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S360 Poster Session IIprocedures, incidences of underutilization and over-allocation
from a scheduling perspective, along with review of overtime
employment of staff, generated further root cause assessment
of several concerning patterns of poor utilization along with
poorly managed spikes in volume which can generate patient
safety risk and employee burn-out. Based on the analysis, a cen-
tralized scheduling process for apheresis was developed and im-
plemented using the existing GE/IDX platform. New guidelines
for apheresis scheduling based on clinical criteria as well as new
rules for scheduling were activated. Restructuring of cell pro-
cessing technical staff work schedules and procedure scheduling
were implemented based on a new assessment of demand and
greater management of procedure scheduling during each pro-
cessing day. Outcomes include significantly greater actual
throughput, improved efficiency of the scheduling process itself,
nearly eliminated overtime, higher staff satisfaction among cell
processing technicians, and reduction of risk-generating volume
spikes.577
OUTPATIENT PHARMACY ESTIMATE OF CHARGE FINANCIAL COUNSEL-
LING
Cruz, E.D., Bramwell, D.P., Shaw, S., Ifokwe, M., Lang, M.,
Lewis, M.S. UT MD Anderson Cancer Center, Houston, TX
Planning for the stem cell transplant (SCT) patient’s discharge is
complex requiring a multidisciplinary team (MDT) approach. Chal-
lenges identified by the MDT include costly prescription co-pays
and limited pharmacy coverage which is overwhelming and frustrat-
ing to patient and MDT.
This challenge led to the creation of a MDT task force. Based on
several meeting discussions and MDT feedback, an outpatient phar-
macy estimate of charge (EOC) process was developed and an EOC
form was designed to address pharmacy co-pays/deductible, high-
dollar prescriptions, annual lifetime maximum and potential dis-
charge medication list, with a goal to counsel all patients prior to
SCT admission.
In October 2009, the Related Coordinator started the new pro-
cess by scheduling the patient’s pharmacy EOC counseling at the
time of pre-admission work-up. The Patient Access Specialist
(PAS) verifies prescription benefits from the health insurance
and reviews coverage with the patient, who signs the EOC form
after counseling. The Patient Access Coordinator addresses ques-
tions related to the medications. The PAS faxes the signed EOC
to the case manager who reviews the EOC with the patient when
planning for discharge. Patients are counseled at the bedside
when appointment is missed. Texas residents who are unable to
financially meet the co-pays/deductible or have limited benefits
are provided with a Supplemental Financial Assistance applica-
tion. The Pharmacy Reimbursement Specialist counsels all Medi-
care, Indigent and Self-pay patients for Pharmacy Assistance
Program.
As a result, patient’s verbalized marked decrease in their anxiety
and increased knowledge on their benefits empowering them to
make informed decisions regarding their discharge prescriptions.
Identification of limited pharmacy coverage prior to SCT admission
enables the MDT timely intervention to address the patient’s di-
lemma. Pharmacy counseling coupled with the EOC form as
a tool enhanced the quality of patient care, increased patient satisfac-
tion and MDT greater job fulfillment.TRANSPLANT NURSING-RESEARCH
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A RANDOMIZED PILOT STUDY COMPARING INFECTION RATES IN MYE-
LOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT PATIENTS RECEIV-
ING A NON-NEUTROPENIC DIET OR A NEUTROPENIC DIET
Lassiter, M., Adler, A. Duke University Health System, Durham, NC
Purpose: The primary objective of this study is to compare the in-
cidence of grade 3 or 4 bacteremia as defined by the NCI CommonTerminology Criteria for Adverse Events (CTCAE) v4.0.in patients
undergoing myeloablative allogeneic stem cell transplant when re-
ceiving a neutropenic diet or a non-neutropenic diet. Secondary ob-
jective is to assess the nutritional status of patients undergoing
myeloablative allogeneic stem cell transplant in those receiving
a neutropenic diet as compared to those receiving a non-neutropenic
diet using the Scored Patient-Generated Subjective Global Assess-
ment (PG-SGA).
Materials andMethods:To date, a convenience sample of 18 mye-
loablative allogeneic hemotopoietic stem cell transplant patients
have been randomized to receive either a neutropenic or non-
neutropenic diet during their period of neutropenia. Several nutri-
tional standard indicators, CBC, and PG-SGAwere assessed weekly.
Blood cultures were obtained per unit standard.
Results: When comparing maximum change in prealbumin, trans-
ferrin, and days of TPN, only borderline statistical difference is de-
tected. Wilcoxon Rank-sums p 5 0.056. The median number of
TPN days for the controls is 18 and for the experimental group
it’s 13, Wilcoxon Rank-sums p5 0.5; therefore, it is not statistically
different. 25% of the controls have a grade 3 blood stream infection
compared to 40% of the experimental, the chi-square test for com-
paring these proportions is 0.50; therefore, these proportions are
not statistically significantly different. No grade 4 blood stream
infections were noted during neutropenia.
Conclusions: This small sample set does not show any significant
difference in grade 3 or 4 infections between the arms of the study.
Days of TPN and overall nutritional status does not appear to be sig-
nificant as well.
Limitations: Small sample size, inconsistent patient recording of
food diaries.
Future directions: Continue enrollment in this study to increase
statistical power of results.579
PALONOSETRON VERSUS ONDANSETRON IN CHEMOTHERAPY INDUCED
NAUSEA AND VOMITTING
Vieira, S., Monroe, D. Trustees of London Clinic, London, United
Kingdom
Introduction: Palonosetron is a longer acting -5 hydroxytrypta-
mine-3 (5-HT3) antagonist, used in preventing chemotherapy in-
duced nausea and vomiting (CINV). It is licensed initially for the
oncology patient group. It is given as an injection and acts over
a five days period.
Method: In our haematology setting we have conducted a small
comparison study to compare the efficiency of Palonosetron and
Ondansetron for haematology patients for preventing CINV. Stage
1 data was collected prospectively for Palonosetron over a year pe-
riod. Second stage data was collected for efficiency of Ondansetron
retrospectively, simply because Ondansetron is the main anti-
sickness drug used in our centre. Patients who were in the Ondan-
setron group were selected randomly without any information
given to ward nurses. The information was collected day 1- day
11 from the day chemotherapy started. There were 24 patients in
each group.
The data was compared in three different categories: complaints of
nausea (severity), vomiting (how many episodes over 24 hour) and
the requirement of additional anti-sickness.
The patients in both groups received similar chemotherapy regi-
mens. Patient demographic data and chemotherapy regimen are
shown Table I.
Result: Due to limited word count of this abstract, the outcome is
evaluated on two sections instead of three: severity of nausea and fre-
quency of vomiting.
According to our study, patients who received Palonosetron suf-
fered less from mild nausea. In this group a maximum of seven pa-
tients reported mild nausea where as 12 patients were reported
similar episodes in the Ondansetron group.
However, in the evaluation of vomiting, there was a trend in the
Palonosetron group. Those patients receiving Palonosetron had
their sickness/ vomiting peak on day 4. Palonosetron was given day
5, where the vomiting subsidised again. However 46% of patients
Poster Session II S361who received Palonosetron have not vomited through out the chemo
while 33% of Ondansetron group.
Conclusion:Even though Palonosetron is manufactured for oncol-
ogy patients, it is used for haematology patients. In our study Pal-
onosetron was compared to Ondansetron. According to our study
Palonosetron made a significant difference in preventing and re-
ducing the CINV. Unfortunately the data was collected retrospec-
tively for the Ondansetron group. Because of low number the
outcome data could not be transferable to the whole patient
group.580
RETROSPECTIVE STUDY TO DEFINE THE ULTIMATE TIMING FOR START-
ING STEM CELL COLLECTION IN THE AUTOLOGOUS SETTING AND TO
COMPARE ENGRAFTMENT DATA OF PATIENTS WHO ACHIEVE TARGET
DOSE IN GREATER THAN 4 VERSUS LESS THAN 4 COLLECTIONS
Smith, V.R., Tran, H.T., Dinh, Y.T., Guillermo-Pacheco, M.,
Rondon, G., Hosing, C.M.University of TexasMDAnderson Cancer Cen-
ter, Houston, TX
Peripheral blood stem cell collection after high dose chemother-
apy for autologous transplantation has been done routinely in
many institutions over the years; however, the criteria for starting
harvest are not standardized. Most institutions agree that circulat-
ing peripheral blood CD34+ cells is the strongest indicator for
planning Apheresis, but the timing of Apheresis collection remains
controversial. Optimization of PBSC collection for autologous
stem cell transplant is necessary for good standard of care and
cost-effectiveness. Most studies have concentrated on identifying
peripheral blood CD34+ thresholds that would result in good cells
yields in fewer apheresis days. Based on these results the apheresis
timing proposed are 5-30 circulating peripheral blood CD34+
cells.
The emergence of new mobilization strategies and rising health-
care costs has brought about a practice change. This tertiary cancer
center did a retrospective study to 1.) determine the optimal timing
for starting PBPC collections by evaluating if patients are more
likely to reach a target number of . / 5 5x106 CD34+ cells if
Apheresis is started when peripheral blood circulating CD34+ cells
are . / 5 15 cells per micro liter compared to starting Apheresis
when peripheral blood circulating CD34+ cells are less than 15 cells
per micro liter. 2.) To evaluate if engraftment is affected when tar-
get dose of . / 5 5x106 CD34+ cells are collected in \ / 5 4
Apheresis days compared to those patients who reach target dose
in . 4 Apheresis days.
In this IRB approved retrospective study we reviewed the chart
of all autologous stem cell transplant patients collected from Jan.
1, 2007-Dec. 31, 2007. We recorded the CD34+ count on the day
of collection and compared to see if there was a significant differ-
ence in the number of stem cells collected between the patients
who were collected with a circulating CD34+ cell count of less
than 15 per micro liter and those who collected with a CD34+
count of 15 or higher. We will correlate to find is there is a sig-
nificant difference in the number apheresis collections required
to collect the target dose, and if there is a difference in engraft-
ment when patients start the apheresis procedure with a circulat-
ing CD34+ cell count of 15 or higher versus those who start
collection when the circulating CD34+ cell count is less than
15. Analysis in ongoing, however preliminary data suggests
that there is not a significance difference in engraftment between
the two groups.581
CAREGIVERS HELPING IN RELIEVING PAIN – C.H.I.R.P. PROJECT
Edmisten, J.H., Prewitt, J., Martin, P.L., Little, K. Duke University
Hospital, Durham, NC
Children who undergo hematopoietic stem cell transplant
experience significant pain and discomfort related to the sideeffects of treatment. Standard methods of analgesia delivery, spe-
cifically patient controlled analgesia (PCA), are not appropriate
for young children as they do not have the cognitive ability to
connect their pain to alleviation with operating a PCA demand
button. Currently, Duke University Hospital policy does not al-
low caregivers to push the button due to concerns for patient
safety. Therefore, an adult caregiver in conjunction with the
nursing staff must assess the pain and intervene for the child.
This process is a setup for delay in pain treatment when nursing
staff are busy with other tasks and unable to push the PCA but-
ton when it is needed.
The CHIRP study will examine the feasibility and acceptance of
caregiver education in operating the PCA demand button in young
pediatric BMT patients who require pain control. This study will
evaluate the preparation of caregivers in assessing their child’s pain
and sedation levels while operating the PCA demand button. The
hypothesis is that inclusion of the family in the delivery of pain med-
ications will yield equivalent or better outcomes and facilitate transi-
tion to home.
Thirty children and families will be enrolled on this IRB approved
protocol. A dedicated study coordinator will provide comprehensive
education using different educational modalities. Materials are pro-
vided in written and video format to review. The focus of the educa-
tion is to provide the caregiver with basic knowledge of pain and
sedation assessment tools, basic knowledge of analgesia and side-ef-
fects, and when to recognize signs of distress. A post-test must be
passed for the caregiver to be an authorized operator of the PCA de-
mand button. Staff education is provided so that they can guide care-
givers with their assessment skills. When patients no longer need
analgesia the caregivers complete a survey to collect 1) their percep-
tions of safety, 2) their ability to determine when their child was in
pain, 3) their perceptions of effective and prompt intervention for
their child’s pain, and 4) overall satisfaction with pain control for
their child.582
THE TRANSITION FROM PARENT TO PATIENT DURING HEMATOPOIETIC
STEM CELL TRANSPLANT
Asmus, K.R. Froedtert Hospital and the Medical College of Wisconsin,
Milwaukee, WI
The experience of being a parent is completely transformed at
the moment of cancer diagnosis, and a greater disequilibrium oc-
curs in the patient’s life when treatment includes a hematopoietic
stem cell transplant (HSCT). A review of the literature sites that
role changes can be greatest for parents raising dependent children
as they quickly transition from parent to patient and attempt to
treat and eradicate their disease, while still trying to grasp and
hold on to the strings of ‘‘normalcy’’ as their child’s parent (Coyne,
2009; Billhult & Segesten, 2003). Today, nurses who care for
HSCT patients continue to observe the treatment to be both phys-
ically and emotionally high-risk due to increased vulnerability of
deadly infections and stress during the prolonged hospitalization.
Although there has been significant research on coping with cancer
treatment, there is only limited research on the specific experience
of parents with dependent children who are treated with a HSCT.
This phenomenon from parent to patient in the environment of
HSCT requires greater research in order to improve nursing care
that is sensitive to the emotional and social changes that result
due to intense treatment, lengthy hospitalization, and restricted in-
teraction with their dependent children in an effort to reduce expo-
sure to infection.
The purpose of this descriptive phenomenological research study
proposes to understand the experience of HSCT treatment and the
physical, emotional, and social changes that transpire for parents
with dependent children; battling to regain health, defeat cancer,
and maintain their role as their child’s parent. The Transition The-
ory (Meleis, 2010) is also incorporated to provide clarity to the phe-
nomenon. Overall, through the proposed research greater nursing
knowledge will be developed to help parents cope with the role
changes during HSCT.
